Shanghai Pharmaceuticals announced that recently, the rivaroxaban tablets produced by its subsidiary Changzhou Pharmaceutical Factory Co., Ltd. received a drug registration certificate issued by the Singapore Health Sciences Authority (HSA), approving the drug for market launch.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Shanghai Pharmaceuticals: Rivaroxaban Tablets Receive Singapore Drug Registration Certificate
Shanghai Pharmaceuticals announced that recently, the rivaroxaban tablets produced by its subsidiary Changzhou Pharmaceutical Factory Co., Ltd. received a drug registration certificate issued by the Singapore Health Sciences Authority (HSA), approving the drug for market launch.